Journal article

Effects of Molecular Heterogeneity on Survival of Patients With BRAF(V600)-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study

Matthew J Wongchenko, Antoni Ribas, Paolo A Ascierto, Brigitte Dreno, Anna Maria di Giacomo, Claus Garbe, Ilsung Chang, Essie Hsu, Isabelle Rooney, William Lu, Hartmut Koeppen, James Larkin, Yibing Yan, Grant A McArthur

JCO PRECISION ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2018

Abstract

Purpose The treatment of advanced BRAFV600-mutated melanomas with BRAF inhibitors (BRAFi) has improved survival, but the efficacy of BRAFi varies among individuals and the development of acquired resistance to BRAFi through reactivation of mitogenactivated protein kinase (MAPK) signaling is common. We performed an exploratory, retrospective analysis to investigate the effects of BRAFV600 allelic balance, coexisting oncogene mutations, cell proliferation signaling levels, and loss of PTEN expression on progression-free survival (PFS) in patients in the phase III coBRIM study, which compared the combination of the MEK inhibitor cobimetinib with the BRAFi vemurafenib versus vemurafenib as monot..

View full abstract

University of Melbourne Researchers